



March 23–24, 2010 • Falls Church, VA

AGENDA

Meeting Objectives:

To bring together representatives from FDA, faculty from leading myeloma centers, as well as biopharmaceutical and diagnostic company representatives to identify:

- Challenges and solutions in the clinical development of next-generation myeloma treatments
- Biomarker strategies in the development of targeted treatment options for myeloma patients

Tuesday, March 23

6:00 PM **Reception**

7:00 PM **Dinner and Guest Speaker**

Personalized Medicine: Lessons Learned Across Cancers

Mara G. Aspinall, MBA

On-Q-ity, Inc.

Wednesday, March 24

7:00 AM **Breakfast and Registration**

8:00 **Welcome and Introductions**

Louise M. Perkins, PhD

Multiple Myeloma Research Foundation

8:10 **Orientation: Current Management of Multiple Myeloma**

Donna E. Reece, MD

Princess Margaret Hospital

University Health Network

8:40 **Industry Perspective: Bortezomib and Beyond in Multiple Myeloma**

Eric Lightcap, PhD

Millennium: The Takeda Oncology Company

9:10 **Industry Perspective: Critical Challenges Facing the Development of
Multiple Myeloma Treatment Options**

Michael G. Kauffman, MD, PhD

Onyx Pharmaceuticals, Inc.

9:40 AM **Break**



March 23–24, 2010 • Falls Church, VA

- 10:00 AM **Panel Discussion**
- **Clinical Trial Designs and Endpoints for Multiple Myeloma in the Current Environment – Challenges and Solutions**
 - Ann Farrell, MD, *U.S. Food and Drug Administration*
 - Mohamad Hussein, MD, *Celgene Corporation*
 - Michael G. Kauffman, MD, PhD
 - Eric Lightcap, PhD
 - Donna E. Reece, MD
- 11:45 **Working Lunch**
- 12:00 PM **Using Genomics to Improve the Health of Patients With Multiple Myeloma**
John D. Shaughnessy Jr, PhD
University of Arkansas for Medical Sciences
- 12:30 **FDA Perspective: Oncology Biomarker Development**
Robert L. Becker, MD
U.S. Food and Drug Administration
- 1:00 **Industry Perspective: Development of Companion Diagnostics for Next Generation Therapeutics**
David R. Parkinson, MD
Nodality
- 1:30 **Industry Perspective: Clinical Activity Observed in a Phase I Dose-Escalation Trial of an Oral MET and ALK Inhibitor, PF-02341066**
Sophia S. B. Randolph, MD, PhD
Pfizer Inc.
- 2:00 **Working Session**
- **Challenges and Opportunities for Integration of Predictive and Prognostic Biomarker Strategies in Multiple Myeloma**
 - Hypothesis generation and clinical validation
 - Early assay implementation and companion diagnostic development
- 3:15 **Discussion, Action Planning, and Wrap-up**
Louise M. Perkins, PhD
- 4:00 PM **Adjournment**

March 23–24, 2010 • Falls Church, VA

BIOGRAPHIES – FACULTY

Mara G. Aspinall, MBA

On-Q-ity, Inc.

Mara G. Aspinall is President and CEO of On-Q-ity, Inc., an innovative diagnostics company dedicated to improving the treatment of individual cancer patients through real time noninvasive monitoring to better target therapy and lower costs. On-Q-ity will enable precise personalized therapeutic decisions across multiple cancers through two core proprietary technologies: (1) microfluidic chip technology that enables the capture, enumeration, and molecular characterization of circulating tumor cells in the bloodstream and (2) validated DNA repair biomarkers that predict treatment response in tissue and blood.

Ms. Aspinall was previously President of Genzyme Genetics, a leading provider of testing services in the oncology and reproductive markets. Ms. Aspinall also served as President of Genzyme Pharmaceuticals.

Ms. Aspinall has been on the Board of Predictive Biosciences since its inception, serving as Chairman for the past year. She is also a Board member of Blue Cross Blue Shield of Massachusetts. She is appointed as Lecturer in Health Care Policy at Harvard Medical School and will teach a seminar series on medicine and business each year. She is an active member of the Federal Secretary of Health and Human Services' Advisory Commission on Genetics, Health and Society as well as a Director of the Personalized Medicine Coalition.

Most recently, Ms. Aspinall co-authored, "Realizing the Promise of Personalized Medicine" in Harvard Business Review. She earned her Master of Business Administration from Harvard Business School and her undergraduate degree in International Relations from Tufts University.

Michael G. Kauffman, MD, PhD

Onyx Pharmaceuticals, Inc.

Michael G. Kauffman, MD, PhD, joined Onyx Pharmaceuticals, Inc., in February 2010 as Chief Medical Officer after serving as the Interim Chief Medical Officer following the acquisition of Proteolix, Inc., in November 2009. Dr. Kauffman was Chief Medical Officer at Proteolix, after having served on their Board of Directors. At Proteolix, he was responsible for the clinical advancement of carfilzomib as well as ONX-912 (PR-047). Prior to joining Proteolix, Dr. Kauffman was President and Chief Executive Officer of EPIX Pharmaceuticals, Inc., from 2002 to 2008. From 1997 to 2002, he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals, Inc., where he played a key role in the development of the proteasome inhibitor Velcade[®]. Earlier in his career, he served as Medical Director at Biogen Corporation. Dr. Kauffman earned his undergraduate



March 23–24, 2010 • Falls Church, VA

BIOGRAPHIES – FACULTY (CONT)

Michael G. Kauffman, MD, PhD (CONT)
Onyx Pharmaceuticals, Inc.

degree in biochemistry from Amherst College and his MD and PhD in molecular biology and biochemistry from Johns Hopkins. He trained in Internal Medicine and Rheumatology at Beth Israel Deaconess Hospital and the Massachusetts General Hospital.

Eric Lightcap, PhD
Millennium: The Takeda Oncology Company

Eric Lightcap, PhD, received his Bachelor of Science in Biochemistry with honors at Indiana University–Bloomington in 1985, his PhD in Biochemistry with Professor Perry Frey at University of Wisconsin–Madison in 1991, and did postdoctoral work with Professor Richard Silverman (inventor of Lyrica[®]) at Northwestern University. Dr. Lightcap joined ProScript in 1997 and began working on biomarker development around Velcade[®] in 1998, focusing initially on the development of the blood 20S proteasome assay used in the clinical development of Velcade. Currently, Dr. Lightcap is working in the Discovery group at Millennium: The Takeda Oncology Company, on applying genomic approaches to understanding mechanism of action and biomarker development of novel therapeutics, including Velcade, MLN9708, and MLN4924.

David R. Parkinson, MD
Nodality

David R. Parkinson, MD, is President and CEO of Nodality, a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and decision-making. Until October 2007, Dr. Parkinson was Senior Vice President, Oncology Research and Development at Biogen Idec. At Biogen Idec, he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously, he had served as Vice President, Oncology Development at Amgen and Vice President, Global Clinical Oncology Development at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec[®], Femara[®], Zometa[®], Kepivance[®], and Vectibix[®]. He previously worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program.

March 23–24, 2010 • Falls Church, VA

BIOGRAPHIES – FACULTY (CONT)

David R. Parkinson, MD (CONT)

Nodality

Dr. Parkinson received his MD as gold medalist from the University of Toronto, Faculty of Medicine, with Internal Medicine and Hematology/Oncology training in Montreal at McGill University and in Boston at New England Medical Center. He is a past Chairman of the U.S. Food and Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA's Cody Medal. He currently serves on the National Cancer Policy Forum of the Institute of Medicine, serves as co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium and is Chairman of the AACR Finance Committee.

Sophia S. B. Randolph, MD, PhD

Pfizer Inc.

Sophia S. B. Randolph MD, PhD, is a Director Oncology/Oncology Business Unit for Pfizer Global Research & Development, and previously served as Director Oncology/Translational Medicine for the pharmaceutical firm. In her role with the company, Dr. Randolph also serves as Lead Clinician and Medical Monitor for Gamma Secretase Inhibitor and Cyclin D Kinase 4/6 Inhibitor EDG programs (hematology/solid tumor), a position she has held since 2008. In this capacity, she acts as medical reviewer for in-licensing opportunities and liaison to Regulatory, Public Relations, Sales and Marketing groups.

Throughout her career, Dr. Randolph worked in various clinical capacities with Merck & Co., Inc., as an acting instructor with the University of Washington Medical Center in Seattle, WA, and as a research associate in the Division of Immunology at the Fred Hutchinson Cancer Research Center, also in Seattle.

Dr. Randolph is a Member, Board of Trustees for The Reuben H. Fleet Science Center in San Diego, CA, and is the co-author of numerous clinical articles published in *Blood*, *Annals of Oncology*, *Cancer Research*, and the *International Journal of Hematology* among others.

Dr. Randolph received her medical degree from the University of Michigan Medical School in Ann Arbor, MI, and graduated from Harvard University with an undergraduate degree in Biochemical Sciences.



March 23–24, 2010 • Falls Church, VA

BIOGRAPHIES – FACULTY (CONT)

Donna E. Reece, MD

*Princess Margaret Hospital
University Health Network*

Donna E. Reece, MD, is Associate Professor and Director of the Program for Multiple Myeloma and Related Diseases in the Department of Medical Oncology and Hematology at Princess Margaret Hospital/University of Toronto. She was awarded the David and Molly Bloom Chair in Multiple Myeloma Research at Princess Margaret Hospital/University Health Network in November 2009.

She earned a Bachelor of Arts degree at the University of Texas, Austin, and graduated as valedictorian with a medical degree from Baylor College of Medicine, Houston, Texas. Dr. Reece then served as Director of the Outpatient Leukemia/Stem Cell Transplant Program, and later Interim Director, of the Blood and Marrow Transplant Program of the Markey Cancer Center at the University of Kentucky, Lexington, KY until her appointment to Princess Margaret Hospital in Toronto in 2001.

Dr. Reece is currently the chair of the Multiple Myeloma Clinical Trials Group of the National Cancer Institute of Canada, member of the US National Cancer Institute Hematology Steering Committee, member of the Scientific Advisory Board of the International Myeloma Foundation, and member of the Clinical Trials Core Medical Review Team as well as the Project Review Committee of the MMRC. She also served for 10 years as co-chair of the Myeloma Working Committee of the International Center for Blood and Marrow Transplant Research.

Her career focus has been in the areas of hematopoietic stem cell transplantation, lymphoid malignancies, and, in particular, plasma cell dyscrasias. She has conducted many clinical trials and published numerous articles in these areas.

John D. Shaughnessy Jr, PhD

University of Arkansas for Medical Sciences

John D. Shaughnessy Jr, PhD, is Professor of Medicine, Director of the Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics; and Director of the Division of Basic Sciences at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences (UAMS) in Little Rock. Dr. Shaughnessy received his PhD in molecular biology through a joint program between the National Cancer Institute's (NCI) Laboratory of Genetics and the University of Maryland. Dr. Shaughnessy's PhD work focused on the molecular-basis of plasma cell malignancies in using the BALB/c plasmacytoma models developed by his mentor, Dr. Michael Potter.



March 23–24, 2010 • Falls Church, VA

BIOGRAPHIES – FACULTY (CONT)

John D. Shaughnessy Jr, PhD (CONT)

University of Arkansas for Medical Sciences

In 2010, Dr. Shaughnessy and Dr. Bart Barlogie founded Myeloma Health, LLC, a diagnostics company that will use gene expression profiling to personalize therapy for patients with myeloma.

Dr. Shaughnessy has published more than 150 peer-reviewed papers in journals such as *Nature Genetics*, *Proceedings of the National Academy of Sciences*, *Cell*, *Cancer Cell*, *The New England Journal of Medicine*, *FASEB Journal*, and also *Blood*, for which he currently serves on the Editorial board. Dr. Shaughnessy has presented over 130 invited lectures at both national and international meetings on translational research in myeloma. Dr. Shaughnessy, his wife Kim, and their four daughters live on a small farm on the edge of the Ouachita National Forrest 25 miles west of Little Rock, AR.

BIOGRAPHIES – MMRF/MMRC

Kathy Giusti, MBA

Multiple Myeloma Research Foundation

Multiple Myeloma Research Consortium

Kathy Giusti is the Founder and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC). In 1998, following her diagnosis with multiple myeloma, Ms. Giusti founded the MMRF to fund innovative myeloma research and drug discovery. Having raised more than \$130 million to date, the MMRF is the world's number one funder of myeloma research. As an extension of the MMRF's mission, Ms. Giusti founded the MMRC in 2004 to enable leading research institutions to work with industry to speed the discovery and development of effective new treatments. Comprising 13 academic institutions across North America, the MMRC is widely recognized for breaking down barriers in tissue banking, data management, genomics, and clinical trials, and is considered an optimal research model to accelerate the development of new therapies. Ms. Giusti received her MBA in general management from Harvard Business School and graduated from the University of Vermont magna cum laude with a Bachelor of Science in Biological Sciences. She began her career in 1980 with Merck & Co., and later joined the Gillette Company.

In 1993, she joined G.D. Searle & Co., where she last served as Executive Director of Searle's worldwide arthritis franchise. Ms. Giusti has received several awards for her efforts to advance medical research and accelerate drug development, including the Centennial Medal for Distinguished



March 23–24, 2010 • Falls Church, VA

BIOGRAPHIES – MMRF/MMRC (CONT)

Kathy Giusti, MBA (CONT)

Multiple Myeloma Research Foundation
Multiple Myeloma Research Consortium

Public Service from the American Association for Cancer Research, the Partners in Progress Award from the American Society of Clinical Oncology, the Healthcare Businesswomen's Association's Woman of the Year Award, and Harvard Business School Entrepreneurial Award. Her efforts have also been recognized by several notable media outlets, including *The Wall Street Journal*, *The New York Times*, *The New Yorker*, *Forbes*, *The Economist*, *Time*, CNBC, CBS Evening News, and NBC Nightly News. Ms. Giusti has served on numerous boards, including the Institute of Medicine's National Cancer Policy Board and the Cancer Leadership Council. Today, she continues to serve on the National Cancer Advisory Board, an appointment she received in 2003 from President George W. Bush, and is a member of the Board of Directors for IMS Health. She lives in Connecticut with her husband, Paul, and her children, Nicole, who is 15, and David, who is 12.

Susan L. Kelley, MD

Multiple Myeloma Research Consortium

Susan L. Kelley, MD, is Chief Medical Officer at the MMRC, where she provides strategic medical leadership for the myeloma research and development activities supported by the MMRC and its sister organization, the MMRF.

Dr. Kelley has more than 20 years of experience in oncology clinical research and drug development within the pharmaceutical industry. Prior to joining the MMRC, Dr. Kelley served as Vice President and head of Global Oncology Clinical Development at Bayer Healthcare Pharmaceuticals, where she was responsible for the worldwide management of the oncology drug development portfolio and for management of Bayer's oncology drug development and franchise strategies. While at Bayer, she oversaw the successful advance of Nexavar[®] (sorafenib) through phase III trials and the FDA approval process. Prior to her position at Bayer, Dr. Kelley held several leadership positions in Bristol-Myers Squibb Clinical Development, both in Oncology and Immunology. She joined the MMRC in 2008.

Dr. Kelley received her medical degree from Duke University School of Medicine. She completed certification in internal medicine at the University of Colorado followed by medical oncology training at the Dana-Farber Cancer Institute in Boston. Prior to joining the pharmaceutical industry, Dr. Kelley also conducted oncology clinical and laboratory research at Yale University School of Medicine.



March 23–24, 2010 • Falls Church, VA

BIOGRAPHIES – MMRF/MMRC (CONT)

Louise M. Perkins, PhD

Multiple Myeloma Research Foundation

Louise M. Perkins, PhD, is Chief Scientific Officer at the MMRF, where she is responsible for the development and execution of the MMRF's research strategy. Dr. Perkins brings more than 16 years of pharmaceutical research experience from two major companies to the MMRF.

Prior to joining the MMRF, she was Director of Cancer Research at Bayer Pharmaceuticals in West Haven, CT, where she contributed to advancing novel targeted therapies toward clinical study, including Nexavar[®] and other innovative signal transduction inhibitors. While at Bayer, she also served as the Director of Research Licensing and was responsible for oncology licensing activities in support of cancer research programs. Prior to joining Bayer, she led a cancer research group at the Schering-Plough Research Institute in Kenilworth, NJ. In this role, she participated in several early-stage research programs including novel target-finding research using human genomics data.

Dr. Perkins graduated from the University of Michigan with a PhD and MS in biological chemistry and conducted postdoctoral studies at Princeton University in the Department of Molecular Biology. She earned her Bachelor of Science in Zoology from the University of North Carolina at Chapel Hill.

Anne Quinn Young, MPH

Multiple Myeloma Research Foundation

Anne Quinn Young, MPH, is Vice President, Communications at the MMRF, where she oversees all communications as well as educational programming for and outreach to healthcare professionals and patients. Anne currently serves as the MMRF's representative on the Cancer Leadership Council (CLC) and as principal investigator on a major grant from the Centers for Disease Control and Prevention (CDC). Prior to joining the MMRF, Anne was a consultant in the Healthcare Practice of Datamonitor, a global market research and business intelligence company. Anne previously worked in healthcare public relations at Burson-Marsteller and Chandler Chicco Agency, following a postgraduate internship at the Department of Justice, Antitrust Division. Anne has a Master of Public Health from the Mailman School of Public Health of Columbia University and graduated cum laude from Dartmouth College with a Bachelor of Arts in Government.



March 23–24, 2010 • Falls Church, VA

BIOGRAPHIES – MMRF/MMRC (CONT)

Joan Levy, PhD

Multiple Myeloma Research Foundation

Joan Levy, PhD, is Associate Director of Research at the MMRF, where she is responsible for the planning and implementation of the MMRF's research agenda. She has more than 20 years of experience in oncology and osteoporosis research in both pharmaceutical and academic settings. Prior to joining the MMRF, Dr. Levy was Technical Director at the Binding Site, where she supported the use of Freelite, a diagnostic assay for multiple myeloma. In addition, she worked at Bayer Pharmaceuticals Corporation in West Haven, CT, for nine years. In that capacity, she was engaged in target identification, compound validation, and project leadership in the fields of cancer and osteoporosis research. She has contributed to the delivery of novel drug candidates for clinical studies in each of these indications. Dr. Levy earned her PhD at the University of Vermont and then completed two postdoctoral fellowships at the Rockefeller University and later at the State University of New York at Stony Brook. Her two academic appointments were at New York University Medical Center and Yale University, studying various aspects of cell signaling pathways involved in the pathogenesis of cancer and development of osteoporosis.

Sandra M. Wear, RN

Multiple Myeloma Research Consortium

Sandra M. Wear, RN, is Associate Director of Operations at the MMRC, where she is responsible for the execution of preclinical and clinical projects within the MMRC. She brings more than 27 years of experience to the MMRC as both an oncology nurse and a senior manager, and has vast experience from both an industry and a contract research organization (CRO) perspective.

She most recently served as Vice President of Regional Monitoring Operations at Endpoint Research in Mississauga, Canada, and Senior Manager of Clinical Process and Training and Trials Management at MannKind Biopharmaceutical Corporation in Danbury, CT. Before this, she served as Associate Director of Clinical Operations at Purdue Pharma, L.P., in Stamford, CT, Sr. Project Manager at Quintiles Transnational Corporation in Mountain View, CA, and Clinical Research Manager at Pharmacia & UpJohn, Inc. in Don Mills, Ontario, Canada.

Ms. Wear received her degree in Nursing from Mohawk Nursing College in Hamilton, Ontario, Canada.



March 23–24, 2010 • Falls Church, VA

PARTICIPANTS – FACULTY

Mara G. Aspinall, MBA

President and CEO
On-Q-ity, Inc.
610 Lincoln St
Waltham, MA 02451
Phone (781) 895-8100
mara.aspinall@on-q-ity.com

Robert L. Becker, MD

U.S. Food and Drug Administration
10903 New Hampshire Ave
Silver Springs, MD 20903
Phone (301) 796-6211
robertl.becker@fda.hhs.gov

Michael G. Kauffman, MD, PhD

Chief Medical Officer
Onyx Pharmaceuticals, Inc.
2100 Powell St
Emeryville, CA 94608
Phone (510) 597-6651
mkauffman@onyx-pharm.com

Eric Lightcap, PhD

Associate Scientific Fellow
Millennium: The Takeda Oncology Company
40 Landsdowne St
Cambridge, MA 02139
Phone (617) 551-3717
eric.lightcap@mpi.com

David R. Parkinson, MD

President and CEO
Nodality
201 Gateway Blvd
South San Francisco, CA 94080
Phone (650) 827-8035
david.parkinson@nodality.com

Sophia S. B. Randolph, MD, PhD

Director, Oncology
Pfizer Inc.
10646 Science Center Dr (CB10)
San Diego, CA 91212
Phone (858) 622-7465
sophia.randolph@pfizer.com

Donna E. Reece, MD

Director, Program for Multiple Myeloma
Related Diseases
Princess Margaret Hospital
University Health Network
610 University Ave
Suite 5-207
Toronto, ON M5G 2M9
Canada
Phone (416) 946-2824
donna.reece@uhn.on.ca

John D. Shaughnessy Jr, PhD

Professor
University of Arkansas for Medical Sciences
4301 W Markham St #776
Little Rock, AR 72205
Phone (501) 296-1503, ext 1457
shaughnessyjohn@uams.edu



March 23–24, 2010 • Falls Church, VA

PARTICIPANTS

Neda Bell, BS

Director – Cooperative Group Clinical
Alliances
Celgene Corporation
86 Morris Ave
Summit, NJ 07901
Phone (908) 673-9161
nbell@celgene.com

Allison Berger, PhD

Senior Scientist I
Millennium: The Takeda Oncology Company
40 Landsdowne St
Cambridge, MA 02139
Phone (617) 926-7275
aberger@mpi.com

David Berman, MD, PhD

Group Director
Bristol-Myers Squibb Company
Route 206 & Province Line Rd
Princeton, NJ 08540
Phone (609) 252-4087
david.berman@bms.com

Catherine Burgess, PhD

Associate Director – Global Regulatory
Strategy
Bristol-Myers Squibb Company
5 Research Pkwy
Mailstop 2DW-203
Wallingford, CT 06492
Phone (203) 677-3835
catherine.burgess@bms.com

John Carpten, PhD

Senior Investigator and Director
TGen
445 North 5th St
Suite 500
Phoenix, AZ 85004
Phone (602) 343-8819
jcarpten@tgen.org

Selina Chen-Kiang, PhD

Professor
Weill-Cornell Medical College
1300 York Ave
Room C-338
New York, NY 10065
Phone (212) 746-6440
sckiang@med.cornell.edu

Mark Cornfeld, MD, MPH

Senior Director
Ortho Biotech Oncology Research &
Development
920 Route 202 S
Raritan, NJ 08869
Phone (908) 218-6956
mcornfel@its.jnj.com

Albert Deisseroth, MD, PhD

Medical Officer Reviewer
U.S. Food and Drug Administration
Division of Drug Oncology Products
10903 New Hampshire Ave
Silver Spring, MD 20854
Phone (301) 796-4864
albert.deisseroth@fda.hhs.gov



March 23–24, 2010 • Falls Church, VA

PARTICIPANTS (CONT)

Joseph Eid, MD

Senior Director, Oncology Clinical Research
Merck Research Laboratories
351 N Sumneytown Pike
Mail Stop UG-4D72
North Wales, PA 19454
Phone (267) 305-1955
joseph_eid@merck.com

Ann Farrell, MD

Deputy Division Director
U.S. Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20903
Phone (301) 796-2330
ann.farrell@fda.hhs.gov

Heidi Gillenwater, MD

Medical Director
Onyx Pharmaceuticals, Inc.
2100 Powell St
Emeryville, CA 94608
Phone (434) 978-4038
hgillenwater@onyx-pharm.com

Mohamad Hussein, MD

Vice President – Hematology
Celgene Corporation
86 Morris Ave
Summit, NJ 07901
Phone (908) 673-8794
mhussein@celgene.com

Robert Kane, MD

Medical Officer
U.S. Food and Drug Administration
Center for Drug Evaluation and Research
123 Crofton Hill Ln
Rockville, MD 20850
Phone (301) 796-1384
robert.kane@fda.hhs.gov

Pam Klein, MD

Chief Medical Officer
Intellikine, Inc.
10931 N Torrey Pines Rd
Suite 103
La Jolla, CA 92037
Phone (858) 768-6528
pam@intellikine.com

Lori Murray

Director, Corporate Communications
Onyx Pharmaceuticals, Inc.
2100 Powell St
Emeryville, CA 94608
Phone (510) 597-6394
lmurray@onyx-pharm.com

Deborah Ricci, PhD

Director, Oncology Biomarkers
Johnson & Johnson
120 Mountain Rd
Ringoes, NJ 08551
Phone (908) 218-7482
dricci@its.jnj.com

Nancy Simonian, MD

Chief Medical Officer
Millennium: The Takeda Oncology Company
40 Landsdowne St
Cambridge, MA 02139
Phone (617) 551-3612
nancy.simonian@mpi.com

Susan Snodgrass, MD

Senior Medical Director
Novartis Oncology
One Health Plaza
Bldg 432
4th Floor/4440
East Hanover, NJ 07936
Phone (862) 778-6385
susan.snodgrass@novartis.com



March 23–24, 2010 • Falls Church, VA

PARTICIPANTS (CONT)

Matthew Spear, MD

Chief Medical Officer
Nereus Pharmaceuticals, Inc.
10480 Wateridge Cir
San Diego, CA 92121
Phone (858) 200-8355
mspear@nereuspharm.com

Peter Sportelli

Vice President, Oncology
Keryx Biopharmaceuticals, Inc.
750 Lexington Ave
20th Floor
New York, NY 10022
Phone (212) 531-5964
psportelli@keryx.com

Craig Tendler, MD

Vice President, Global Medical Affairs,
Oncology
Johnson & Johnson Pharmaceutical
Services, LLC
700 U.S. Highway 202 S
Raritan, NJ 08869
Phone (908) 927-4772
ctendler@its.jnj.com

Suzanne Trudel, MD, MSc, FRCPS

Assistant Professor of Medicine
Princess Margaret Hospital
University Health Network
620 University Ave
8th Floor, Room 201
Toronto, ON M5G 2C1
Canada
Phone (416) 946-4566
strudel@uhnres.utoronto.ca

Ravi Vij, MD

Assistant Professor
Washington University School of Medicine
Section of BMT and Leukemia
660 S Euclid Ave
Campus Box 8007
St. Louis, MO 63110
Phone (314) 454-8323
rvij@im.wustl.edu

Duncan Walker, PhD

Senior Director of Translational Medicine
Array BioPharma Inc.
3200 Walnut St
Boulder, CO 80301
Phone (303) 386-1414
dwalker@arraybiopharma.com

Denise Williams, MD

Executive Director
Novartis Pharmaceuticals
One Health Plaza
Bldg 432 - 4340B
East Hanover, NJ 07936
Phone (862) 778-3749
denise.williams@novartis.com

Hong Xie, MD, MS, MBA

Associate Director
Ortho Biotech Oncology Research and
Development
200 Great Valley Pkwy
Maildrop C-5-2
Malvern, PA 19355
Phone (610) 240-4093
hxie57@its.jnj.com



March 23–24, 2010 • Falls Church, VA

PARTICIPANTS – MMRF/MMRC

Kathy Giusti, MBA

Founder and CEO
Multiple Myeloma Research Foundation
Multiple Myeloma Research Consortium
383 Main Ave
Fifth Floor
Norwalk, CT 06851
Phone (203) 229-0464
giustik@themmrf.org

Susan L. Kelley, MD

Chief Medical Officer
Multiple Myeloma Research Consortium
383 Main Ave
Fifth Floor
Norwalk, CT 06851
Phone (203) 652-0213
kelleys@themmrf.org

Louise M. Perkins, PhD

Chief Scientific Officer
Multiple Myeloma Research Foundation
383 Main Ave
Fifth Floor
Norwalk, CT 06851
Phone (203) 652-0208
perkinsl@themmrf.org

Anne Quinn Young, MPH

Vice President, Communications
Multiple Myeloma Research Foundation
383 Main Ave
Fifth Floor
Norwalk, CT 06851
Phone (203) 652-0212
quinnyounga@themmrf.org

Joan Levy, PhD

Associate Director of Research
Multiple Myeloma Research Foundation
383 Main Ave
Fifth Floor
Norwalk, CT 06851
Phone (203) 652-0233
levyj@themmrf.org

Sandra M. Wear, RN

Associate Director, Operations
Multiple Myeloma Research Consortium
383 Main Ave
Fifth Floor
Norwalk, CT 06851
Phone (203) 652-0237
wears@themmrc.org



March 23–24, 2010 • Falls Church, VA

PARTICIPANTS – AOI COMMUNICATIONS, L.P.

Thomas J. Burke

President
AOI Communications, L.P.
415 Eagleview Blvd
Suite 110
Exton, PA 19341
Phone (610) 321-1623, ext 11
tburke@aoic.net

Tammy Dempsey

Director, Client Service
AOI Communications, L.P.
415 Eagleview Blvd
Suite 110
Exton, PA 19341
Phone (610) 321-1623, ext 18
tdempsey@aoic.net

Michelle DiMichele

Client Service Manager
AOI Communications, L.P.
415 Eagleview Blvd
Suite 110
Exton, PA 19341
Phone (610) 321-1623, ext 17
mdimichele@aoic.net

Robin Lukert

Client Service Manager
AOI Communications, L.P.
415 Eagleview Blvd
Suite 110
Exton, PA 19341
Phone (610) 321-1623, ext 33
rlukert@aoic.net